Labcorp Bolsters Liquid Biopsy Capabilities With $450M PGDx Acquisition

Benzinga2021-12-23

Laboratory Corp of America Holdings has agreed to acquire Personal Genome Diagnostics Inc (PGDx), a cancer genomics firm with a portfolio of comprehensive liquid biopsy and tissue-based products.

  • Labcorp will pay $450 million in cash at closing and up to an additional $125 million on achieving future performance milestones.
  • The addition of PGDx complements & accelerates Labcorp’s existing liquid biopsy capabilities and expands its oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities.
  • PGDx offers the only diagnostic kit cleared by the FDA for pan-solid cancer comprehensive tumor profiling using a 500+ gene panel.
  • PGDx 2021 revenues are expected to be approximately $22 million, with projected revenues for 2022 expected to be nearly $40 million.
  • Labcorp expects the acquisition to be slightly dilutive to its adjusted EPS over the next couple of years and provide returns over its cost of capital by year five.
  • The transaction is expected to close in 1H of 2022.
  • Price Action: LH shares closed higher by 0.54% at $304.22 on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
13